Medical Management of Peripheral Artery Disease

Abstract

Peripheral artery disease (PAD) is a common type of atherosclerotic disease of the lower extremities associated with reduced quality of life and ambulatory capacity. Major adverse cardiovascular events and limb amputations are the leading cause of morbidity and mortality in this population. Optimal medical therapy is therefore critical in these patients to prevent adverse events. Risk factor modifications, including blood pressure control and smoking cessation, in addition to antithrombotic agents, peripheral vasodilators, and supervised exercise therapy are key pillars of medical therapy. Revascularization procedures represent key touch points between patients and health care providers and serve as opportunities to optimize medical therapy and improve long-term patency rates and outcomes. This review summarizes the aspects of medical therapy that all providers should be familiar with when caring for patients with PAD in the peri-revascularization period.

Keywords

peripheral artery disease - medical management - antithrombotic therapy - smoking cessation - supervised exercise therapy - interventional radiology

Publikationsverlauf

Artikel online veröffentlicht:
16. Juni 2023

• References

• 1 Gerhard-Herman MD, Gornik HL, Barrett C. et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017; 69 (11) 1465-1508
• 2 Wu A, Coresh J, Selvin E. et al. Lower extremity peripheral artery disease and quality of life among older individuals in the community. J Am Heart Assoc 2017; 6 (01) 6
• 3 Gutierrez JA, Mulder H, Jones WS. et al. Polyvascular disease and risk of major adverse cardiovascular events in peripheral artery disease: a secondary analysis of the EUCLID trial. JAMA Netw Open 2018; 1 (07) e185239
• 4 Berger JS, Ladapo JA. Underuse of prevention and lifestyle counseling in patients with peripheral artery disease. J Am Coll Cardiol 2017; 69 (18) 2293-2300
• 5 Singh N, Ding L, Devera J, Magee GA, Garg PK. Prescribing of statins after lower extremity revascularization procedures in the US. JAMA Netw Open 2021; 4 (12) e2136014
• 6 Armstrong EJ, Wu J, Singh GD. et al. Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease. J Vasc Surg 2014; 60 (06) 1565-1571
• 7 Lu L, Mackay DF, Pell JP. Meta-analysis of the association between cigarette smoking and peripheral arterial disease. Heart 2014; 100 (05) 414-423
• 8 Creager MA, Hamburg NM. Smoking cessation improves outcomes in patients with peripheral artery disease. JAMA Cardiol 2022; 7 (01) 15-16
• 9 Ding N, Sang Y, Chen J. et al. Cigarette smoking, smoking cessation, and long-term risk of 3 major atherosclerotic diseases. J Am Coll Cardiol 2019; 74 (04) 498-507
• 10 Conte MS, Pomposelli FB. Society for Vascular Surgery Practice guidelines for atherosclerotic occlusive disease of the lower extremities management of asymptomatic disease and claudication. Introduction. J Vasc Surg 2015; 61 (3, Suppl): 1S
• 11 Hennrikus D, Joseph AM, Lando HA. et al. Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial. J Am Coll Cardiol 2010; 56 (25) 2105-2112
• 12 Anthenelli RM, Benowitz NL, West R. et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 2016; 387 (10037): 2507-2520
• 13 Patnode CD, Henderson JT, Thompson JH, Senger CA, Fortmann SP, Whitlock EP. Behavioral counseling and pharmacotherapy interventions for tobacco cessation in adults, including pregnant women: a review of reviews for the U.S. Preventive Services Task Force. Ann Intern Med 2015; 163 (08) 608-621
• 14 Aday AW, Everett BM. Dyslipidemia profiles in patients with peripheral artery disease. Curr Cardiol Rep 2019; 21 (06) 42
• 15 Aday AW, Lawler PR, Cook NR, Ridker PM, Mora S, Pradhan AD. Lipoprotein particle profiles, standard lipids, and peripheral artery disease incidence. Circulation 2018; 138 (21) 2330-2341
• 16 Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, Wilson PW. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J 2002; 143 (06) 961-965
• 17 Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from the Framingham Heart Study. Circulation 1997; 96 (01) 44-49
• 18 Smith I, Franks PJ, Greenhalgh RM, Poulter NR, Powell JT. The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischaemia. Eur J Vasc Endovasc Surg 1996; 11 (04) 402-408
• 19 Grundy SM, Stone NJ, Bailey AL. et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139 (25) e1046-e1081
• 20 Pedersen TR, Kjekshus J, Pyörälä K. et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998; 81 (03) 333-335
• 21 Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007; 45 (04) 645-654 , discussion 653–654
• 22 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9326): 7-22
• 23 Arya S, Khakharia A, Binney ZO. et al. Association of statin dose with amputation and survival in patients with peripheral artery disease. Circulation 2018; 137 (14) 1435-1446
• 24 Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag 2012; 8: 415-427
• 25 Cannon CP, Blazing MA, Giugliano RP. et al; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372 (25) 2387-2397
• 26 West AM, Anderson JD, Meyer CH. et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis 2011; 218 (01) 156-162
• 27 Bonaca MP, Nault P, Giugliano RP. et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation 2018; 137 (04) 338-350
• 28 Schwartz GG, Steg PG, Szarek M. et al; ODYSSEY OUTCOMES Committees and Investigators*. Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. Circulation 2020; 141 (20) 1608-1617
• 29 Schandelmaier S, Briel M, Saccilotto R. et al. Niacin for primary and secondary prevention of cardiovascular events. Cochrane Database Syst Rev 2017; 6 (06) CD009744
• 30 Ginsberg HN, Elam MB, Lovato LC. et al; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362 (17) 1563-1574
• 31 Miller M, Stone NJ, Ballantyne C. et al; American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011; 123 (20) 2292-2333
• 32 Siscovick DS, Barringer TA, Fretts AM. et al; American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation 2017; 135 (15) e867-e884
• 33 Bhatt DL, Steg PG, Miller M. et al; REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019; 380 (01) 11-22
• 34 Nicholls SJ, Lincoff AM, Garcia M. et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH Randomized Clinical Trial. JAMA 2020; 324 (22) 2268-2280
• 35 Bostrom JA, Beckman JA, Berger JS. Summoning STRENGTH to question the placebo in REDUCE-IT. Circulation 2021; 144 (06) 407-409
• 36 Nording HM, Seizer P, Langer HF. Platelets in inflammation and atherogenesis. Front Immunol 2015; 6: 98
• 37 Weissler EH, Mulder H, Rockhold FW. et al. Understanding study drug discontinuation through EUCLID. Front Cardiovasc Med 2022; 9: 947645
• 38 Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009; 301 (18) 1909-1919
• 39 Fowkes FG, Price JF, Stewart MC. et al; Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010; 303 (09) 841-848
• 40 Belch J, MacCuish A, Campbell I. et al; Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840
• 41 Catalano M, Born G, Peto R. Critical Leg Ischaemia Prevention Study (CLIPS) Group. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med 2007; 261 (03) 276-284
• 42 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324 (7329): 71-86
• 43 Bonaca MP, Bauersachs RM, Anand SS. et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 2020; 382 (21) 1994-2004
• 44 Anand SS, Caron F, Eikelboom JW. et al. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS Trial. J Am Coll Cardiol 2018; 71 (20) 2306-2315
• 45 Eikelboom JW, Connolly SJ, Bosch J. et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377 (14) 1319-1330
• 46 Anand SS, Bosch J, Eikelboom JW. et al; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391 (10117): 219-229
• 47 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348 (9038): 1329-1339
• 48 Wallentin L, Becker RC, Budaj A. et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11) 1045-1057
• 49 Patel MR, Becker RC, Wojdyla DM. et al. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: data from the PLATO Trial. Eur J Prev Cardiol 2015; 22 (06) 734-742
• 50 Hiatt WR, Fowkes FG, Heizer G. et al; EUCLID Trial Steering Committee and Investigators. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 2017; 376 (01) 32-40
• 51 Bhatt DL, Fox KA, Hacke W. et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354 (16) 1706-1717
• 52 Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA. CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 2009; 30 (02) 192-201
• 53 Belch JJ, Dormandy J, Biasi GM. et al; CASPAR Writing Committee. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010; 52 (04) 825-833 , 833.e1–833.e2
• 54 Fanari Z, Malodiya A, Weiss SA, Hammami S, Kolm P, Weintraub WS. Long-term use of dual antiplatelet therapy for the secondary prevention of atherothrombotic events: meta-analysis of randomized controlled trials. Cardiovasc Revasc Med 2017; 18 (01) 10-15
• 55 Hiatt WR, Bonaca MP, Patel MR. et al. Rivaroxaban and aspirin in peripheral artery disease lower extremity revascularization: impact of concomitant clopidogrel on efficacy and safety. Circulation 2020; 142 (23) 2219-2230
• 56 Narula N, Dannenberg AJ, Olin JW. et al. Pathology of peripheral artery disease in patients with critical limb ischemia. J Am Coll Cardiol 2018; 72 (18) 2152-2163
• 57 Anand SS, Yusuf S, Pogue J, Weitz JI, Flather M. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. Circulation 1998; 98 (11) 1064-1070
• 58 Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347 (13) 969-974
• 59 Anand S, Yusuf S, Xie C. et al; Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357 (03) 217-227
• 60 Mega JL, Braunwald E, Wiviott SD. et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366 (01) 9-19
• 61 Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002; 90 (12) 1314-1319
• 62 Brown T, Forster RB, Cleanthis M, Mikhailidis DP, Stansby G, Stewart M. Cilostazol for intermittent claudication. Cochrane Database Syst Rev 2021; 6 (06) CD003748
• 63 Pande RL, Hiatt WR, Zhang P, Hittel N, Creager MA. A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Vasc Med 2010; 15 (03) 181-188
• 64 Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: a study in long-term effects). J Vasc Surg 2008; 47 (02) 330-336
• 65 Packer M, Carver JR, Rodeheffer RJ. et al; The PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325 (21) 1468-1475
• 66 Whelton PK, Carey RM, Aronow WS. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2018; 138 (17) e426-e483
• 67 Fudim M, Hopley CW, Huang Z. et al. Association of hypertension and arterial blood pressure on limb and cardiovascular outcomes in symptomatic peripheral artery disease: the EUCLID Trial. Circ Cardiovasc Qual Outcomes 2020; 13 (09) e006512
• 68 Itoga NK, Tawfik DS, Lee CK, Maruyama S, Leeper NJ, Chang TI. Association of blood pressure measurements with peripheral artery disease events. Circulation 2018; 138 (17) 1805-1814
• 69 Bavry AA, Anderson RD, Gong Y. et al. Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension 2010; 55 (01) 48-53
• 70 Ostergren J, Sleight P, Dagenais G. et al; HOPE Study Investigators. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004; 25 (01) 17-24
• 71 Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342 (03) 145-153
• 72 Yusuf S, Teo KK, Pogue J. et al; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358 (15) 1547-1559
• 73 Treat-Jacobson D, McDermott MM, Beckman JA. et al; American Heart Association Council on Peripheral Vascular Disease; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; and Council on Lifestyle and Cardiometabolic Health. Implementation of supervised exercise therapy for patients with symptomatic peripheral artery disease: a science advisory from the American Heart Association. Circulation 2019; 140 (13) e700-e710
• 74 Regensteiner JG, Hiatt WR, Coll JR. et al. The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program. Vasc Med 2008; 13 (01) 15-24
• 75 McDermott MM, Liu K, Greenland P. et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA 2004; 292 (04) 453-461
• 76 McDermott MM, Ades P, Guralnik JM. et al. Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial. JAMA 2009; 301 (02) 165-174
• 77 McDermott MM, Ferrucci L, Tian L. et al. Effect of granulocyte-macrophage colony-stimulating factor with or without supervised exercise on walking performance in patients with peripheral artery disease: the PROPEL Randomized Clinical Trial. JAMA 2017; 318 (21) 2089-2098
• 78 Fakhry F, van de Luijtgaarden KM, Bax L. et al. Supervised walking therapy in patients with intermittent claudication. J Vasc Surg 2012; 56 (04) 1132-1142
• 79 Perkins JM, Collin J, Creasy TS, Fletcher EW, Morris PJ. Exercise training versus angioplasty for stable claudication. Long and medium term results of a prospective, randomised trial. Eur J Vasc Endovasc Surg 1996; 11 (04) 409-413
• 80 Murphy TP, Cutlip DE, Regensteiner JG. et al; CLEVER Study Investigators. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation 2012; 125 (01) 130-139
• 81 Mazari FA, Khan JA, Samuel N. et al. Long-term outcomes of a randomized clinical trial of supervised exercise, percutaneous transluminal angioplasty or combined treatment for patients with intermittent claudication due to femoropopliteal disease. Br J Surg 2017; 104 (01) 76-83
• 82 Spronk S, Bosch JL, den Hoed PT, Veen HF, Pattynama PM, Hunink MG. Intermittent claudication: clinical effectiveness of endovascular revascularization versus supervised hospital-based exercise training -- randomized controlled trial. Radiology 2009; 250 (02) 586-595
• 83 Saratzis A, Paraskevopoulos I, Patel S. et al. Supervised exercise therapy and revascularization for intermittent claudication: network meta-analysis of randomized controlled trials. JACC Cardiovasc Interv 2019; 12 (12) 1125-1136
• 84 Klaphake S, Fakhry F, Rouwet EV. et al. Long-term follow-up of a randomized clinical trial comparing endovascular revascularization plus supervised exercise with supervised exercise only for intermittent claudication. Ann Surg 2020; 276 (06) e1035-e1043
• 85 Hageman D, Fokkenrood HJ, Gommans LN, van den Houten MM, Teijink JA. Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudication. Cochrane Database Syst Rev 2018; 4 (04) CD005263
• 86 Gardner AW, Parker DE, Montgomery PS, Scott KJ, Blevins SM. Efficacy of quantified home-based exercise and supervised exercise in patients with intermittent claudication: a randomized controlled trial. Circulation 2011; 123 (05) 491-498
• 87 Mays RJ, Rogers RK, Hiatt WR, Regensteiner JG. Community walking programs for treatment of peripheral artery disease. J Vasc Surg 2013; 58 (06) 1678-1687
• 88 Sabatine MS, Giugliano RP, Keech AC. et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376 (18) 1713-1722